On 2 September 2026, Ocumension Therapeutics (OCUMENSION-B, 01477.HK) announced that its Phase III clinical trial of OT-211 (TRYPTYR, acoltremon ophthalmic solution 0.003%) in China has completed enrollment of an aggregate of 398 patients; the drug is the first TRPM8 agonist approved by the US FDA for the treatment of dry eye disease, and the company secured an exclusive license for the Chinese mainland through a strategic collaboration with Alcon in October 2024.
On 2 September 2026, Global Bio-chem Technology Group Company Limited (GLOBAL BIO-CHEM, 00809.HK) announced that the completion and ignition ceremony of its boiler renovation project was held at its Dehui production base in Jilin Province on 31 August 2026, with the renovated boilers formally put into operation; civil works for the coenzyme Q10 project commenced on the same day, under which its indirect wholly-owned subsidiary Dacheng Dahe produces CoQ10 mycelium for Shenzhou Bio-tech Co., Ltd., marking the Group's entry into synthetic biology and its expansion into medical applications.
On 2 September 2026, Estun Automation Co., Ltd. (ESTUN, 02715.HK) published an overseas regulatory announcement in which its A-share unit (002747) disclosed a plan to repurchase and cancel an aggregate of 322,300 restricted shares held by 21 grantees (10 who had resigned and 11 with a performance grade of B); upon completion, total shares will fall from 968,666,053 to 968,343,753 and registered capital will decrease to RMB 96,834.3753 ten-thousand yuan, with creditors entitled within 45 days of the announcement to require debt repayment or guarantees.
On 2 September 2026, Xinhua News Media Holdings Limited (XH NEWS MEDIA, 00309.HK) announced a placing of up to 5,830,348 new shares at HKD 0.8 per share on a best effort basis, representing a discount of approximately 13.98% to the closing price of HKD 0.93 and approximately 11.19% of the issued share capital, with estimated net proceeds of approximately HKD 4.564 million for general working capital. The placing does not require shareholders' approval and is conditional upon Listing Committee approval, with completion expected on the third business day after all conditions are satisfied.
On 2 September 2026, KEYTOP PARKING (02272.HK) announced that it had filed an application with the CSRC for H-share full circulation, planning to convert all of its 2,857,040 unlisted shares with a par value of RMB 1.0 each into H shares for listing and trading on the Main Board of the Stock Exchange. No further shareholders' meeting is required for the conversion and listing, implementation details are yet to be finalized, and completion remains subject to approvals from relevant domestic and overseas regulators.
On 2 September 2026, Cofoe Medical Technology Co., Ltd. (COFOE MEDICAL, 01187.HK) published an overseas regulatory announcement in which its A-share (301087) results briefing revealed that the second A-share buyback of the year would be fully cancelled while the controlling shareholder increased its H-share holding, and that the company had secured Philips brand licensing for seven health monitoring categories in Greater China, with the first products completing registration. Shareholders totaled approximately 15,000 as of 31 August 2026.
On 2 September 2026, Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA, 02637.HK) announced that HX9428 had filed a Phase IIa IND for diabetic macular edema with the CDE of NMPA on 31 August 2026; the Phase I dose-escalation study in neovascular age-related macular degeneration was fully completed, with 13 patients finishing 24 weeks of dosing without additional intravitreal injections and average visual acuity improvement exceeding 5 letters. The drug has received Fast Track Designation from the US FDA.
On 2 September 2026, China Huajun Group Limited (CHINAHUAJUNGP, 00377.HK) completed a debt capitalization, issuing 94 million capitalization shares to creditors at HKD 1.0 per share, representing approximately 50.14% of the enlarged issued share capital; total shares rose from 93,491,851 to 187,491,851, diluting controlling shareholder Huajun Group's stake from 47.54% to 23.71%. A whitewash waiver was also applied for in connection with the share issue.
On September 2, Hong Kong's three major indices declined across the board, with the Hang Seng Index edging down 0.07% to 25,311.21 points and the Hang Seng TECH Index falling 0.74%, on turnover of HKD 216.691 billion. Biotech stocks stood out, with Biocytogen up 11.52% and Simcere Pharma up 7.64% after the company signed a global licensing agreement with Roche worth more than USD 1.53 billion. Auto stocks were broadly under pressure, with Li Auto hitting a new low since its Hong Kong listing. Southbound capital recorded net buying of HKD 4.093 billion. In the quarterly review of the FTSE China 50 Index, Hua Hong Grace and Montage Tech were added, effective September 18; NIO's second-quarter revenue rose 69% year on year; and Haichang Ocean Park will be removed from Stock Connect from September 7.
On September 2, 2026, aerospace and defense ETFs led the Shanghai-Shenzhen Stock Connect ETFs market with marginal gains. ChinaAMC CNI Aerospace Industry ETF (159227.SZ) rose 1.27%, while Penghua Guozheng Food industry ETF (159698.SZ) plunged 5.81%; rare metals and chemical ETFs broadly fell more than 2.6%. NewTimeSpace monitoring shows an extreme rotation pattern in which military ETFs took over with slight gains while the previous day's hot sectors retreated across the board.
On 2 September 2026, C HEALTH GP (08225.HK) voluntarily disclosed the progress of its receivables collection: receivables totalled RMB 128 million as of the end of 2024 (fully provisioned); arbitration claims against related parties were dismissed and an application to set aside the award has been filed; RMB 2.088 million was newly collected since 3 June 2026; and a "Receivables Management Committee" has been established, with asset tracing and legal recovery initiated against customers with full bad debt provisions.
On 2 September 2026, SC HOLDINGS (00413.HK) announced that the High Court held a hearing on the same day on two winding-up petitions against its subsidiary Huasheng Toys, ordering that the first petition be adjourned to 16 September 2026 and that the second petition be withdrawn pursuant to the petitioner's summons; the Company will publish further announcements on the progress of the first petition in due course.
On 2 September 2026, SUNSHINE OIL (02012.HK) disclosed in a supplemental announcement that the winding-up petition was filed by Ms. Zhu Huiwen, a bond investor and independent third party, with the Company owing USD 657,298.55 (approximately HKD 5.13 million) as of the petition date; the Company aims to resolve the petition on or before 14 October 2026 and considers that it has sufficient resources to fully repay the debt.
On 2 September 2026, MOG DIGITECH (01942.HK) announced the results of its rights issue: approximately 27.73% of the rights shares were subscribed, and 495,878,000 unsubscribed rights shares were placed to 6 independent placees at HKD 0.065 per share, raising net proceeds of approximately HKD 43.2 million (50% to be injected into the financing services business and 50% for working capital); trading in the fully paid rights shares is expected to commence on 4 September.
On 2 September 2026, VIEWTRIX TECH (03310.HK) announced the initiation of a proposed A-share listing, having entered into a coaching agreement with GF Securities.
On 2 September 2026, HONGHUA GROUP (00196.HK) announced that its subsidiary Sichuan Honghua has signed drilling rig sales agreements with a Middle East customer totalling RMB 600 million, with the rigs to be equipped with self-developed intelligent systems.
